Items where Funder is NHS Health Technology Assessment.

The University of Leeds

Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, McParland, L et al. (9 more authors) (2017) Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. Report. National Institute for Health Research , Health Technology Assessment. ISSN 1366-5278

Rodgers, H, Howel, D, Bhattarai, N et al. (14 more authors) (2019) Evaluation of an Extended Stroke Rehabilitation Service (EXTRAS). Stroke, 50 (12). pp. 3561-3568. ISSN 0039-2499

Burton, L.-J., Forster, A. orcid.org/0000-0001-7466-4414, Johnson, J. et al. (2 more authors) (2025) Using the Behaviour Change Wheel to develop an intervention to improve conversations about recovery on the stroke unit. PLOS ONE, 20 (1). e0317087. ISSN 1932-6203